The research was led by the ARC-Net Research Centre of the University Hospital of Verona, Italy, with significant contributions from the University of Glasgow.
Researchers found there were a significant number of inherited mutations in this type of cancer - 17 per cent of PaNETs cases looked at were linked to inherited faulty genes.
Previously it was thought only 5 per cent of tumours were linked to hereditary genes.
Using international expertise the study also discovered how mutations affected different genes and their functions.
Also Read
NETs are relatively rare and represent less than 0.5 per cent of all malignant tumours. They are low-incidence tumours, but with high prevalence, often because patients live for many years with the disease.
The study was coordinated by the Veronese multi centre team of Arc-Net, led by Professor Aldo Scarpa, which brought together pancreatic cancer expertise from around the world.
Professor Scarpa said: "In this study we studied 160 PaNETs. By sequencing the genome of these tumours we have decrypted the landscape of genetic alterations of these tumours. This discovery will allow us to target the development of specific therapies that aim to counter the alterations identified".
"We managed to overcome all the societal hurdles of data and material sharing to make significant findings in an uncommon cancer type that can be difficult to treat," Biankin said.
One of the most provocative findings is that these cancers had a larger than expected inherited gene defect that likely contributed to their development, potentially raising challenges in the clinic and refocusing future studies in the area.
Disclaimer: No Business Standard Journalist was involved in creation of this content